PRESENTED BY:

University Hospitals
Cleveland Medical Center

SPONSORED BY:

CASE WESTERN RESERVE UNIVERSITY

CONTINUING MEDICAL EDUCATION

SCT Multiple Myeloma Meeting - 11/25/2026 – 81194-78575

Date: November 25, 2026
Time: 8:00 AM-9:00 AM

UH Cleveland Medical Center

Timothy O'brien, MD
University Hospitals

Educational Objectives
At the conclusion of this activity, the participant should be better able to:
1 Apply recent trial data to inform the clinical application of the two FDA-approved BCMA CAR T cells-idecel and cilta-cel.
2 Identify key mechanisms of BCMA CAR T resistance.
3 Review recent updates to pivotal MM studies, particularly CAR T studies, presented at the International Myeloma Society meeting.

Accreditation and Credit Designation Statements
Case Western Reserve University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Case Western Reserve University School of Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures:
All relevant financial relationships have been mitigated. This activity's planners and speaker(s) have made the following disclosures:

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Lauren Brister, MSN, APRN-CNP	Other Planning Committee Member	Honoraria-Horizon CME - 06/02/2026
Brenda Cooper, MD	Course Director	Nothing to disclose - 06/02/2026
Molly Gallogly, MD, PhD	Other Planning Committee Member	Speakers Bureau-Incyte|Consulting Fee-Techspert|Speakers Bureau-Lilly|Honoraria-MJH Life Sciences (Relationship has ended)|Membership on Advisory Committees or Review

© University Hospitals CME 00025

		Panels, Board Membership, etc.-Sanofi - 05/27/2026
James J Ignatz-Hoover , MD, PhD	Other Planning Committee Member	Speakers Bureau-Sanofi-Aventis|Speakers Bureau-Regeneron - 06/01/2026
Christina Luszcak, PharmD	Other Planning Committee Member	Honoraria-Syndax (Relationship has ended) - 05/29/2026
Leland Metheny, MD	Other Planning Committee Member	Speakers Bureau-Incyte (Relationship has ended)|Speakers Bureau-Taiho (Relationship has ended)|Advisor-Bristol-Myers Squibb (Relationship has ended)|Advisor-Gamida (Relationship has ended) - 06/02/2026
Timothy O'Brien, MD	Faculty, Other Planning Committee Member	Nothing to disclose - 05/28/2026
Benjamin Tomlinson, MD	Other Planning Committee Member	Advisor-Bristol-Myers Squib Aventis (Relationship has ended) - 06/25/2026
Koen van Besien, MD, PhD	Other Planning Committee Member	Stocks or stock options, excluding diversified mutual funds-Hemogenyx|Stocks or stock options, excluding diversified mutual funds-Avertix|Advisor-autolus|Advisor-ADC Therapeutics|Advisor-intellia (Relationship has ended)|Advisor-morphosys (Relationship has ended)|Advisor-crispr (Relationship has ended)|Advisor-incyte (Relationship has ended)|Advisor-adbio - 09/23/2026